1,1-cyclopentanedimethaneamine | 38932-72-8

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 1,1-cyclopentanedimethaneamine
• 英文别名: (1-(aminomethyl)cyclopentyl)methanamine；1,1-cyclopentanedimethanamine；C-(1-aminomethyl-cyclopentyl)-methylamine；[1-(Aminomethyl)cyclopentyl]methanamine
• CAS: 38932-72-8
• 化学式: C₇H₁₆N₂
• 分子量: 128.217
• InChiKey: CSMSTXROIMQHME-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  9
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  52
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1,1-cyclopentanedimethaneamine 在 sodium hypochlorite 、 双氧水 作用下， 以 甲醇 、 水 为溶剂， 生成 2,3-二氮杂-螺[4.4]壬-2-烯
  参考文献：
  名称：

  N′-(Arylsulfonyl)pyrazoline-1-carboxamidines as Novel, Neutral 5-Hydroxytryptamine 6 Receptor (5-HT₆R) Antagonists with Unique Structural Features

  摘要：

  The 5-HT6 receptor (5-HT6R) has been in the spotlight for several years regarding CNS-related diseases. We set out to discover novel, neutral 5-HT6R antagonists to improve off-target selectivity compared to basic amine-containing scaffolds dominating the field. High-throughput screening identified the N'-(sulfonyl)pyrazoline-1-carboxamidine scaffold as a promising neutral core for starting hit-to-lead. Medicinal chemistry, molecular modeling, small molecule NMR and X-ray crystallography were subsequently applied to optimize the leads into antagonists (compounds 1-49) displaying high 5-HT6R affinity with optimal off-target selectivity. Unique structural features include a pseudoaromatic system and an internal hydrogen bond freezing the bioactive conformation. While physicochemical properties and CNS availability were generally favorable, significant efforts had to be made to improve metabolic stability. The optimized structure 42 is an extremely selective, hERG-free, high-affinity 5-HT6R antagonist showing good human in vitro metabolic stability. Rat pharrnacokinetic data were sufficiently good to enable further in vivo profiling.

  DOI：

  10.1021/jm200466r
• 作为产物：
  描述：

  环戊烷-1,1-二甲腈 在 lithium aluminium tetrahydride 作用下， 以 四氢呋喃 为溶剂， 生成 1,1-cyclopentanedimethaneamine
  参考文献：
  名称：

  新型抗疟药 2-氨基丙基氨基喹诺酮类药物前瞻性性能预测的设计和测试。

  摘要：

  迫切需要提高药物开发的效率，而在疟疾等被忽视的疾病方面，这一需求最为明显。疟原虫中嘧啶代谢的特性使得抑制二氢乳清酸脱氢酶 (DHODH) 成为抗疟药物设计的一个有吸引力的目标。通过应用一对互补的定量构效关系来抑制恶性疟原虫(s- Pf ) 中截短的可溶形式的酶DHODH）从针对培养的寄生虫的大规模表型筛选数据中，我们能够识别出一类抑制酶并消除血液培养中寄生虫生长的抗疟药。设计和合成了扩展该类别的新型类似物，目的是提高效力以及一般药代动力学和毒理学特征。他们的合成也代表了一个机会，可以前瞻性地验证我们的计算机属性预测。所合成的七种类似物的理化性质与预测结果非常吻合，其中五种对血液培养中生长的恶性疟原虫的活性比已发表的先导系列中的任何一种化合物都更有效。制备的特定类似物不抑制 s- PfDHODH 在体外，但先进的生物测定表明，该类的其他例子确实抑制了与线粒体膜结合的完整Pf DHODH。然而，新的类似物在预期Pf

  DOI：

  10.1007/s10822-020-00333-x

文献信息

• Amide inhibitors of leukotriene A4 hydrolase
  申请人：Chen Ming

  公开号：US20070155727A1

  公开（公告）日：2007-07-05

  This invention is directed to compounds of formula (I): where r, q, R, R 2 , R 3 , R 4a , R 4b , R 4c , R 5a , R 5b , R 5c , R 6a , R 6b , R 6c , R 7 , R 8 , R 9 and R 10 are described herein, or pharmaceutically acceptable salts, solvates, polymorphs, ammonium ions, N-oxides or prodrugs thereof; which are leukotriene A 4 hydrolase inhibitors and which are therefore useful in treating inflammatory disorders. Pharmaceutical compositions comprising the compounds of the invention and methods of using and preparing the compounds of the invention are also disclosed.

  本发明涉及的化合物的化学式为（I）：其中r、q、R、R2、R3、R4a、R4b、R4c、R5a、R5b、R5c、R6a、R6b、R6c、R7、R8、R9和R10如本文所述，或其药学上可接受的盐、溶剂化合物、多晶形、铵离子、N-氧化物或其前药；这些化合物是白三烯A4水解酶抑制剂，因此在治疗炎症性疾病方面具有用途。本发明还涉及包含所述化合物的药物组合物以及使用和制备所述化合物的方法。
• (Ethylene)-(propylene) - triaminepentaacetic acid derivatives, process for their production, and their use for the production of pharmaceutical agents
  申请人：Schering AG

  公开号：US20030194371A1

  公开（公告）日：2003-10-16

  The invention relates to (ethylene)-(propylene)-triaminepentaacetic acid derivatives that are substituted on both the ethylene bridge and the propylene bridge, as well as conjugates of these compounds with biomolecules. The compounds and conjugates are suitable as agents for NMR diagnosis and radiodiagnosis as well as for radiotherapy.

  该发明涉及在乙烯桥和丙烯桥上取代的(乙烯)-(丙烯)-三胺五乙酸衍生物，以及这些化合物与生物分子的结合物。这些化合物和结合物适用于核磁共振诊断和放射诊断代理，以及放射治疗。
• Platinum complexes of amines with dibasic acids
  申请人：American Cyanamid Company

  公开号：US04675336A1

  公开（公告）日：1987-06-23

  Novel organic compounds of the formula ##STR1## Where R.sub.1 and R.sub.2 are individually selected from the group consisting of hydrogen and alkyl(C.sub.1 -C.sub.6); or R.sub.1 and R.sub.2 taken together are selected from the group consisting of ##STR2## where n is an integer 3-6, ##STR3## where m is an integer 3-6, and ##STR4## and L is selected from the group consisting of --O--, --CH.sub.2 --, ##STR5## where R.sub.3 is alkyl(C.sub.1 -C.sub.6) or --CH.sub.2 CH.sub.2 OH, which have antineoplastic activity, compositions containing the compounds and method of using the compounds to treat tumors in mammals.

  化合物的化学式为##STR1##其中R.sub.1和R.sub.2分别选择自氢和烷基(C.sub.1-C.sub.6)组成的群; 或者R.sub.1和R.sub.2一起选择自##STR2##其中n是整数3-6，##STR3##其中m是整数3-6，以及##STR4##和L是选择自--O--，--CH.sub.2--，##STR5##其中R.sub.3是烷基(C.sub.1-C.sub.6)或--CH.sub.2 CH.sub.2 OH，具有抗肿瘤活性，含有这些化合物的组合物以及使用这些化合物治疗哺乳动物肿瘤的方法。
• Platinum complexes of amines with novel dibasic acids
  申请人：American Cyanamid Company

  公开号：US04866092A1

  公开（公告）日：1989-09-12

  Novel organic compounds of the formula ##STR1## where R.sub.1 and R.sub.2 are individually selected from the group consisting of hydrogen and alkyl(C.sub.1 -C.sub.6); or R.sub.1 and R.sub.2 taken together are selected from the group consisting of ##STR2## where n is an integer 3-6, ##STR3## where m is an integer 3-6, and ##STR4## and L is selected from the group consisting of --O--, --CH.sub.2 --, ##STR5## and >NR.sub.3 where R.sub.3 is alkyl(C.sub.1 -C.sub.6) or --CH.sub.2 CH.sub.2 OH, which have antineoplastic activity, compositions containing the compounds and methods of using the compounds to treat tumors in mammals.

  该专利描述了一种新的有机化合物，其化学式为## STR1##其中R.sub.1和R.sub.2分别选择自氢和烷基(C.sub.1-C.sub.6);或者R.sub.1和R.sub.2组合在一起，选择自## STR2##其中n是整数3-6，## STR3##其中m是整数3-6，以及## STR4##并且L选择自--O--，--CH.sub.2--，## STR5##以及>NR.sub.3，其中R.sub.3是烷基(C.sub.1-C.sub.6)或--CH.sub.2 CH.sub.2 OH。这些化合物具有抗肿瘤活性，本专利还涉及含有这些化合物的组合物以及使用这些化合物治疗哺乳动物肿瘤的方法。
• SULFONYLPYRAZOLE AND SULFONYLPYRAZOLINE CARBOXAMIDINE DERIVATIVES AS 5-HT6 ANTAGONISTS
  申请人：Van Loevezijn Arnold

  公开号：US20080311179A1

  公开（公告）日：2008-12-18

  This invention concerns compounds of the general formula (1). and derivatives thereof, which are antagonists of 5-HT 6 receptors, wherein the symbols have the meanings given in the description. The invention also concerns methods for the preparation of these compounds, to novel intermediates useful for their synthesis, and to uses of such compounds and compositions, particularly their use in administering them to patients to achieve a therapeutic effect in treating at least on disease or condition chosen from Parkinson's disease, Huntington's chorea, schizophrenia, anxiety, depression, manic depression, psychoses, epilepsy, obsessive compulsive disorders, mood disorders, migraine, Alzheimer's disease, age related cognitive decline, mild cognitive impairment, sleep disorders, eating disorders, anorexia, bulimia, binge eating disorders, panic attacks, akathisia, attention deficit hyperactivity disorder, attention deficit disorder, withdrawal from abuse of cocaine, ethanol, nicotine or benzodiazepines, pain, disorders associated with spinal trauma or head injury, hydrocephalus, functional bowel disorder, Irritable Bowel Syndrome, obesity and type-2 diabetes.

  本发明涉及通式（1）的化合物及其衍生物，它们是5-HT6受体拮抗剂，其中符号的含义如说明书所示。本发明还涉及制备这些化合物的方法，对于其合成有用的新型中间体，以及这些化合物和组合物的用途，特别是将它们用于向患者施用以达到治疗帕金森病、亨廷顿舞蹈症、精神分裂症、焦虑、抑郁症、躁郁症、精神病、癫痫、强迫症、情绪障碍、偏头痛、阿尔茨海默病、与年龄相关的认知衰退、轻度认知障碍、睡眠障碍、进食障碍、厌食症、贪食症、暴食症、惊恐发作、不安定症、注意力缺陷多动障碍、注意力缺陷障碍、戒断可卡因、乙醇、尼古丁或苯二氮平的滥用、疼痛、与脊髓损伤或头部损伤有关的疾病、脑积水、功能性肠道障碍、肠易激综合征、肥胖症和2型糖尿病等至少一种疾病或症状的治疗效果。